OpGen (NASDAQ:OPGN) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage presently has a $3.00 target price on the medical research company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.94% from the company’s current price.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
OPGN has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of OpGen in a research note on Monday, March 15th. Alliance Global Partners lifted their price target on OpGen from $5.65 to $7.00 and gave the company a “buy” rating in a research note on Monday, March 8th.
OpGen (NASDAQ:OPGN) last announced its quarterly earnings data on Wednesday, March 24th. The medical research company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.06). OpGen had a negative net margin of 586.99% and a negative return on equity of 154.05%. On average, equities analysts expect that OpGen will post -1.49 EPS for the current year.
An institutional investor recently bought a new position in OpGen stock. Schonfeld Strategic Advisors LLC acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 54,000 shares of the medical research company’s stock, valued at approximately $114,000. Schonfeld Strategic Advisors LLC owned about 0.24% of OpGen as of its most recent SEC filing. 2.29% of the stock is currently owned by institutional investors and hedge funds.
OpGen Company Profile
OpGen, Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It also engages in the development of molecular information products and services for global healthcare settings. It also offers guidance to clinicians about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs).
Recommended Story: What do I need to know about analyst ratings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.